Ceramic Mosaic Tile
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
Global Osteoarthritis Pain Drugs Market Outlook 2023
1 Osteoarthritis Pain Drugs Market Overview
1.1 Product Overview and Scope of Osteoarthritis Pain Drugs
1.2 Osteoarthritis Pain Drugs Segment by Type
1.2.1 Global Osteoarthritis Pain Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Oral
1.2.3 Injection
1.2.4 External
1.3 Osteoarthritis Pain Drugs Segment by Application
1.3.1 Global Osteoarthritis Pain Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Medical Care
1.3.3 Personal Care
1.4 Global Osteoarthritis Pain Drugs Market Size Estimates and Forecasts
1.4.1 Global Osteoarthritis Pain Drugs Revenue 2016-2027
1.4.2 Global Osteoarthritis Pain Drugs Sales 2016-2027
1.4.3 Osteoarthritis Pain Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Osteoarthritis Pain Drugs Market Competition by Manufacturers
2.1 Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Osteoarthritis Pain Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Osteoarthritis Pain Drugs Manufacturing Sites, Area Served, Product Type
2.5 Osteoarthritis Pain Drugs Market Competitive Situation and Trends
2.5.1 Osteoarthritis Pain Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Osteoarthritis Pain Drugs Players Market Share by Revenue
2.5.3 Global Osteoarthritis Pain Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Osteoarthritis Pain Drugs Retrospective Market Scenario by Region
3.1 Global Osteoarthritis Pain Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Osteoarthritis Pain Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.3.1 North America Osteoarthritis Pain Drugs Sales by Country
3.3.2 North America Osteoarthritis Pain Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.4.1 Europe Osteoarthritis Pain Drugs Sales by Country
3.4.2 Europe Osteoarthritis Pain Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Osteoarthritis Pain Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Osteoarthritis Pain Drugs Sales by Region
3.5.2 Asia Pacific Osteoarthritis Pain Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.6.1 Latin America Osteoarthritis Pain Drugs Sales by Country
3.6.2 Latin America Osteoarthritis Pain Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Osteoarthritis Pain Drugs Sales by Country
3.7.2 Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Osteoarthritis Pain Drugs Historic Market Analysis by Type
4.1 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2016-2021)
4.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Osteoarthritis Pain Drugs Price by Type (2016-2021)
5 Global Osteoarthritis Pain Drugs Historic Market Analysis by Application
5.1 Global Osteoarthritis Pain Drugs Sales Market Share by Application (2016-2021)
5.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Osteoarthritis Pain Drugs Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 SK Chemicals
6.3.1 SK Chemicals Corporation Information
6.3.2 SK Chemicals Description and Business Overview
6.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
6.3.5 SK Chemicals Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Crystal Genomics
6.6.1 Crystal Genomics Corporation Information
6.6.2 Crystal Genomics Description and Business Overview
6.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
6.6.5 Crystal Genomics Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Sino Biopharmaceutical
6.8.1 Sino Biopharmaceutical Corporation Information
6.8.2 Sino Biopharmaceutical Description and Business Overview
6.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.8.5 Sino Biopharmaceutical Recent Developments/Updates
6.9 Haohai Biological
6.9.1 Haohai Biological Corporation Information
6.9.2 Haohai Biological Description and Business Overview
6.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
6.9.5 Haohai Biological Recent Developments/Updates
6.10 Zhejiang Chengyi Pharmaceutical
6.10.1 Zhejiang Chengyi Pharmaceutical Corporation Information
6.10.2 Zhejiang Chengyi Pharmaceutical Description and Business Overview
6.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments/Updates
6.11 Freda
6.11.1 Freda Corporation Information
6.11.2 Freda Osteoarthritis Pain Drugs Description and Business Overview
6.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
6.11.5 Freda Recent Developments/Updates
6.12 Bright Future
6.12.1 Bright Future Corporation Information
6.12.2 Bright Future Osteoarthritis Pain Drugs Description and Business Overview
6.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
6.12.5 Bright Future Recent Developments/Updates
6.13 Jingfeng Pharmaceutical
6.13.1 Jingfeng Pharmaceutical Corporation Information
6.13.2 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.13.5 Jingfeng Pharmaceutical Recent Developments/Updates
6.14 Chugai Pharmaceutical
6.14.1 Chugai Pharmaceutical Corporation Information
6.14.2 Chugai Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.14.5 Chugai Pharmaceutical Recent Developments/Updates
6.15 Mikasa Seiyaku
6.15.1 Mikasa Seiyaku Corporation Information
6.15.2 Mikasa Seiyaku Osteoarthritis Pain Drugs Description and Business Overview
6.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
6.15.5 Mikasa Seiyaku Recent Developments/Updates
6.16 Taisho Pharmaceutical
6.16.1 Taisho Pharmaceutical Corporation Information
6.16.2 Taisho Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.16.5 Taisho Pharmaceutical Recent Developments/Updates
6.17 Seikagaku Corporation
6.17.1 Seikagaku Corporation Corporation Information
6.17.2 Seikagaku Corporation Osteoarthritis Pain Drugs Description and Business Overview
6.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
6.17.5 Seikagaku Corporation Recent Developments/Updates
6.18 GlaxoSmithKline
6.18.1 GlaxoSmithKline Corporation Information
6.18.2 GlaxoSmithKline Osteoarthritis Pain Drugs Description and Business Overview
6.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
6.18.5 GlaxoSmithKline Recent Developments/Updates
6.19 Eli Lilly
6.19.1 Eli Lilly Corporation Information
6.19.2 Eli Lilly Osteoarthritis Pain Drugs Description and Business Overview
6.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
6.19.5 Eli Lilly Recent Developments/Updates
6.20 Novartis
6.20.1 Novartis Corporation Information
6.20.2 Novartis Osteoarthritis Pain Drugs Description and Business Overview
6.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
6.20.5 Novartis Recent Developments/Updates
6.21 Horizon Pharma
6.21.1 Horizon Pharma Corporation Information
6.21.2 Horizon Pharma Osteoarthritis Pain Drugs Description and Business Overview
6.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
6.21.5 Horizon Pharma Recent Developments/Updates
6.22 Abbott
6.22.1 Abbott Corporation Information
6.22.2 Abbott Osteoarthritis Pain Drugs Description and Business Overview
6.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
6.22.5 Abbott Recent Developments/Updates
6.23 Mylan
6.23.1 Mylan Corporation Information
6.23.2 Mylan Osteoarthritis Pain Drugs Description and Business Overview
6.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
6.23.5 Mylan Recent Developments/Updates
6.24 Daiichi Sankyo
6.24.1 Daiichi Sankyo Corporation Information
6.24.2 Daiichi Sankyo Osteoarthritis Pain Drugs Description and Business Overview
6.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
6.24.5 Daiichi Sankyo Recent Developments/Updates
6.25 TEVA
6.25.1 TEVA Corporation Information
6.25.2 TEVA Osteoarthritis Pain Drugs Description and Business Overview
6.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
6.25.5 TEVA Recent Developments/Updates
6.26 Almatica Pharma
6.26.1 Almatica Pharma Corporation Information
6.26.2 Almatica Pharma Osteoarthritis Pain Drugs Description and Business Overview
6.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
6.26.5 Almatica Pharma Recent Developments/Updates
6.27 Astellas Pharma
6.27.1 Astellas Pharma Corporation Information
6.27.2 Astellas Pharma Osteoarthritis Pain Drugs Description and Business Overview
6.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
6.27.5 Astellas Pharma Recent Developments/Updates
6.28 Tide Pharmaceutical
6.28.1 Tide Pharmaceutical Corporation Information
6.28.2 Tide Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.28.5 Tide Pharmaceutical Recent Developments/Updates
6.29 Iroko Pharmaceuticals
6.29.1 Iroko Pharmaceuticals Corporation Information
6.29.2 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Description and Business Overview
6.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
6.29.5 Iroko Pharmaceuticals Recent Developments/Updates
6.30 Hengrui Pharmaceutical
6.30.1 Hengrui Pharmaceutical Corporation Information
6.30.2 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.30.5 Hengrui Pharmaceutical Recent Developments/Updates
7 Osteoarthritis Pain Drugs Manufacturing Cost Analysis
7.1 Osteoarthritis Pain Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Osteoarthritis Pain Drugs
7.4 Osteoarthritis Pain Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Osteoarthritis Pain Drugs Distributors List
8.3 Osteoarthritis Pain Drugs Customers
9 Osteoarthritis Pain Drugs Market Dynamics
9.1 Osteoarthritis Pain Drugs Industry Trends
9.2 Osteoarthritis Pain Drugs Growth Drivers
9.3 Osteoarthritis Pain Drugs Market Challenges
9.4 Osteoarthritis Pain Drugs Market Restraints
10 Global Market Forecast
10.1 Osteoarthritis Pain Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Osteoarthritis Pain Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Osteoarthritis Pain Drugs by Type (2022-2027)
10.2 Osteoarthritis Pain Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Osteoarthritis Pain Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Osteoarthritis Pain Drugs by Application (2022-2027)
10.3 Osteoarthritis Pain Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Osteoarthritis Pain Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Osteoarthritis Pain Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Osteoarthritis Pain Drugs Sales (M Dose) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Osteoarthritis Pain Drugs Sales (M Dose) Comparison by Application (2021-2027)
Table 3. Global Osteoarthritis Pain Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Osteoarthritis Pain Drugs Covered in This Study
Table 5. Global Osteoarthritis Pain Drugs Sales (M Dose) of Key Manufacturers (2016-2021)
Table 6. Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Osteoarthritis Pain Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Osteoarthritis Pain Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Osteoarthritis Pain Drugs Average Price (US$/Dose) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Osteoarthritis Pain Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Osteoarthritis Pain Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Osteoarthritis Pain Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Osteoarthritis Pain Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Osteoarthritis Pain Drugs Sales by Region (2016-2021) & (M Dose)
Table 16. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Osteoarthritis Pain Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Osteoarthritis Pain Drugs Sales by Country (2016-2021) & (M Dose)
Table 19. North America Osteoarthritis Pain Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Osteoarthritis Pain Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Osteoarthritis Pain Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Osteoarthritis Pain Drugs Sales by Country (2016-2021) & (M Dose)
Table 23. Europe Osteoarthritis Pain Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Osteoarthritis Pain Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Osteoarthritis Pain Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Osteoarthritis Pain Drugs Sales by Region (2016-2021) & (M Dose)
Table 27. Asia Pacific Osteoarthritis Pain Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Osteoarthritis Pain Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Osteoarthritis Pain Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Osteoarthritis Pain Drugs Sales by Country (2016-2021) & (M Dose)
Table 31. Latin America Osteoarthritis Pain Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Osteoarthritis Pain Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Osteoarthritis Pain Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Osteoarthritis Pain Drugs Sales by Country (2016-2021) & (M Dose)
Table 35. Middle East and Africa Osteoarthritis Pain Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Osteoarthritis Pain Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Osteoarthritis Pain Drugs Sales (M Dose) by Type (2016-2021)
Table 39. Global Osteoarthritis Pain Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Osteoarthritis Pain Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Osteoarthritis Pain Drugs Revenue Share by Type (2016-2021)
Table 42. Global Osteoarthritis Pain Drugs Price (US$/Dose) by Type (2016-2021)
Table 43. Global Osteoarthritis Pain Drugs Sales (M Dose) by Application (2016-2021)
Table 44. Global Osteoarthritis Pain Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Osteoarthritis Pain Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Osteoarthritis Pain Drugs Revenue Share by Application (2016-2021)
Table 47. Global Osteoarthritis Pain Drugs Price (US$/Dose) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 51. Pfizer Osteoarthritis Pain Drugs Product
Table 52. Pfizer Recent Developments/Updates
Table 53. Bayer Corporation Information
Table 54. Bayer Description and Business Overview
Table 55. Bayer Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 56. Bayer Osteoarthritis Pain Drugs Product
Table 57. Bayer Recent Developments/Updates
Table 58. SK Chemicals Corporation Information
Table 59. SK Chemicals Description and Business Overview
Table 60. SK Chemicals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 61. SK Chemicals Osteoarthritis Pain Drugs Product
Table 62. SK Chemicals Recent Developments/Updates
Table 63. GSK Corporation Information
Table 64. GSK Description and Business Overview
Table 65. GSK Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 66. GSK Osteoarthritis Pain Drugs Product
Table 67. GSK Recent Developments/Updates
Table 68. Sanofi Corporation Information
Table 69. Sanofi Description and Business Overview
Table 70. Sanofi Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 71. Sanofi Osteoarthritis Pain Drugs Product
Table 72. Sanofi Recent Developments/Updates
Table 73. Crystal Genomics Corporation Information
Table 74. Crystal Genomics Description and Business Overview
Table 75. Crystal Genomics Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 76. Crystal Genomics Osteoarthritis Pain Drugs Product
Table 77. Crystal Genomics Recent Developments/Updates
Table 78. Johnson & Johnson Corporation Information
Table 79. Johnson & Johnson Description and Business Overview
Table 80. Johnson & Johnson Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 81. Johnson & Johnson Osteoarthritis Pain Drugs Product
Table 82. Johnson & Johnson Recent Developments/Updates
Table 83. Sino Biopharmaceutical Corporation Information
Table 84. Sino Biopharmaceutical Description and Business Overview
Table 85. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 86. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product
Table 87. Sino Biopharmaceutical Recent Developments/Updates
Table 88. Haohai Biological Corporation Information
Table 89. Haohai Biological Description and Business Overview
Table 90. Haohai Biological Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 91. Haohai Biological Osteoarthritis Pain Drugs Product
Table 92. Haohai Biological Recent Developments/Updates
Table 93. Zhejiang Chengyi Pharmaceutical Corporation Information
Table 94. Zhejiang Chengyi Pharmaceutical Description and Business Overview
Table 95. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 96. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product
Table 97. Zhejiang Chengyi Pharmaceutical Recent Developments/Updates
Table 98. Freda Corporation Information
Table 99. Freda Description and Business Overview
Table 100. Freda Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 101. Freda Osteoarthritis Pain Drugs Product
Table 102. Freda Recent Developments/Updates
Table 103. Bright Future Corporation Information
Table 104. Bright Future Description and Business Overview
Table 105. Bright Future Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 106. Bright Future Osteoarthritis Pain Drugs Product
Table 107. Bright Future Recent Developments/Updates
Table 108. Jingfeng Pharmaceutical Corporation Information
Table 109. Jingfeng Pharmaceutical Description and Business Overview
Table 110. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 111. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product
Table 112. Jingfeng Pharmaceutical Recent Developments/Updates
Table 113. Chugai Pharmaceutical Corporation Information
Table 114. Chugai Pharmaceutical Description and Business Overview
Table 115. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 116. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product
Table 117. Chugai Pharmaceutical Recent Developments/Updates
Table 118. Mikasa Seiyaku Corporation Information
Table 119. Mikasa Seiyaku Description and Business Overview
Table 120. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 121. Mikasa Seiyaku Osteoarthritis Pain Drugs Product
Table 122. Mikasa Seiyaku Recent Developments/Updates
Table 123. Taisho Pharmaceutical Corporation Information
Table 124. Taisho Pharmaceutical Description and Business Overview
Table 125. Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 126. Taisho Pharmaceutical Osteoarthritis Pain Drugs Product
Table 127. Taisho Pharmaceutical Recent Developments/Updates
Table 128. Seikagaku Corporation Corporation Information
Table 129. Seikagaku Corporation Description and Business Overview
Table 130. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 131. Seikagaku Corporation Osteoarthritis Pain Drugs Product
Table 132. Seikagaku Corporation Recent Developments/Updates
Table 133. GlaxoSmithKline Corporation Information
Table 134. GlaxoSmithKline Description and Business Overview
Table 135. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 136. GlaxoSmithKline Osteoarthritis Pain Drugs Product
Table 137. GlaxoSmithKline Recent Developments/Updates
Table 138. Eli Lilly Corporation Information
Table 139. Eli Lilly Description and Business Overview
Table 140. Eli Lilly Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 141. Eli Lilly Osteoarthritis Pain Drugs Product
Table 142. Eli Lilly Recent Developments/Updates
Table 143. Novartis Corporation Information
Table 144. Novartis Description and Business Overview
Table 145. Novartis Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 146. Novartis Osteoarthritis Pain Drugs Product
Table 147. Novartis Recent Developments/Updates
Table 148. Horizon Pharma Corporation Information
Table 149. Horizon Pharma Description and Business Overview
Table 150. Horizon Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 151. Horizon Pharma Osteoarthritis Pain Drugs Product
Table 152. Horizon Pharma Recent Developments/Updates
Table 153. Abbott Corporation Information
Table 154. Abbott Description and Business Overview
Table 155. Abbott Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 156. Abbott Osteoarthritis Pain Drugs Product
Table 157. Abbott Recent Developments/Updates
Table 158. Mylan Corporation Information
Table 159. Mylan Description and Business Overview
Table 160. Mylan Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 161. Mylan Osteoarthritis Pain Drugs Product
Table 162. Mylan Recent Developments/Updates
Table 163. Daiichi Sankyo Corporation Information
Table 164. Daiichi Sankyo Description and Business Overview
Table 165. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 166. Daiichi Sankyo Osteoarthritis Pain Drugs Product
Table 167. Daiichi Sankyo Recent Developments/Updates
Table 168. TEVA Corporation Information
Table 169. TEVA Description and Business Overview
Table 170. TEVA Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 171. TEVA Osteoarthritis Pain Drugs Product
Table 172. TEVA Recent Developments/Updates
Table 173. Almatica Pharma Corporation Information
Table 174. Almatica Pharma Description and Business Overview
Table 175. Almatica Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 176. Almatica Pharma Osteoarthritis Pain Drugs Product
Table 177. Almatica Pharma Recent Developments/Updates
Table 178. Astellas Pharma Corporation Information
Table 179. Astellas Pharma Description and Business Overview
Table 180. Astellas Pharma Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 181. Astellas Pharma Osteoarthritis Pain Drugs Product
Table 182. Astellas Pharma Recent Developments/Updates
Table 183. Tide Pharmaceutical Corporation Information
Table 184. Tide Pharmaceutical Description and Business Overview
Table 185. Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 186. Tide Pharmaceutical Osteoarthritis Pain Drugs Product
Table 187. Tide Pharmaceutical Recent Developments/Updates
Table 188. Iroko Pharmaceuticals Corporation Information
Table 189. Iroko Pharmaceuticals Description and Business Overview
Table 190. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 191. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product
Table 192. Iroko Pharmaceuticals Recent Developments/Updates
Table 193. Hengrui Pharmaceutical Corporation Information
Table 194. Hengrui Pharmaceutical Description and Business Overview
Table 195. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Revenue (Million US$), Price (US$/Dose) and Gross Margin (2016-2021)
Table 196. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product
Table 197. Hengrui Pharmaceutical Recent Developments/Updates
Table 198. Production Base and Market Concentration Rate of Raw Material
Table 199. Key Suppliers of Raw Materials
Table 200. Osteoarthritis Pain Drugs Distributors List
Table 201. Osteoarthritis Pain Drugs Customers List
Table 202. Osteoarthritis Pain Drugs Market Trends
Table 203. Osteoarthritis Pain Drugs Growth Drivers
Table 204. Osteoarthritis Pain Drugs Market Challenges
Table 205. Osteoarthritis Pain Drugs Market Restraints
Table 206. Global Osteoarthritis Pain Drugs Sales Forecast by Type (2022-2027) & (M Dose)
Table 207. Global Osteoarthritis Pain Drugs Sales Market Share Forecast by Type (2022-2027)
Table 208. Global Osteoarthritis Pain Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 209. Global Osteoarthritis Pain Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 210. Global Osteoarthritis Pain Drugs Sales Forecast by Application (2022-2027) & (M Dose)
Table 211. Global Osteoarthritis Pain Drugs Sales Market Share Forecast by Application (2022-2027)
Table 212. Global Osteoarthritis Pain Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 213. Global Osteoarthritis Pain Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 214. Global Osteoarthritis Pain Drugs Sales Forecast by Region (2022-2027) & (M Dose)
Table 215. Global Osteoarthritis Pain Drugs Sales Market Share Forecast by Region (2022-2027)
Table 216. Global Osteoarthritis Pain Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 217. Global Osteoarthritis Pain Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 218. Research Programs/Design for This Report
Table 219. Key Data Information from Secondary Sources
Table 220. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Osteoarthritis Pain Drugs
Figure 2. Global Osteoarthritis Pain Drugs Market Share by Type in 2020 & 2027
Figure 3. Oral Product Picture
Figure 4. Injection Product Picture
Figure 5. External Product Picture
Figure 6. Global Osteoarthritis Pain Drugs Market Share by Application in 2020 & 2027
Figure 7. Medical Care
Figure 8. Personal Care
Figure 9. Global Osteoarthritis Pain Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Osteoarthritis Pain Drugs Market Size 2016-2027 (US$ Million)
Figure 11. Global Osteoarthritis Pain Drugs Sales 2016-2027 (M Dose)
Figure 12. Global Osteoarthritis Pain Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 13. Osteoarthritis Pain Drugs Sales Share by Manufacturers in 2020
Figure 14. Global Osteoarthritis Pain Drugs Revenue Share by Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Osteoarthritis Pain Drugs Players: Market Share by Revenue in 2020
Figure 16. Osteoarthritis Pain Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 17. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2016-2021)
Figure 18. Global Osteoarthritis Pain Drugs Sales Market Share by Region in 2020
Figure 19. Global Osteoarthritis Pain Drugs Revenue Market Share by Region (2016-2021)
Figure 20. Global Osteoarthritis Pain Drugs Revenue Market Share by Region in 2020
Figure 21. U.S. Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Canada Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Germany Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. France Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. U.K. Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Italy Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Russia Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. China Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Japan Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. South Korea Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. India Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Australia Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. China Taiwan Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Indonesia Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Thailand Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Malaysia Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Mexico Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Brazil Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Argentina Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Turkey Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Saudi Arabia Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. UAE Osteoarthritis Pain Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Sales Market Share of Osteoarthritis Pain Drugs by Type (2016-2021)
Figure 44. Sales Market Share of Osteoarthritis Pain Drugs by Application (2016-2021)
Figure 45. Sales Market Share of Osteoarthritis Pain Drugs by Application in 2020
Figure 46. Revenue Share of Osteoarthritis Pain Drugs by Application (2016-2021)
Figure 47. Revenue Share of Osteoarthritis Pain Drugs by Application in 2020
Figure 48. Manufacturing Cost Structure of Osteoarthritis Pain Drugs
Figure 49. Manufacturing Process Analysis of Osteoarthritis Pain Drugs
Figure 50. Osteoarthritis Pain Drugs Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer Bayer SK Chemicals GSK Sanofi Crystal Genomics Johnson & Johnson Sino Biopharmaceutical Haohai Biological Zhejiang Chengyi Pharmaceutical Freda Bright Future Jingfeng Pharmaceutical Chugai Pharmaceutical Mikasa Seiyaku Taisho Pharmaceutical Seikagaku Corporation GlaxoSmithKline Eli Lilly Novartis Horizon Pharma Abbott Mylan Daiichi Sankyo TEVA Almatica Pharma Astellas Pharma Tide Pharmaceutical Iroko Pharmaceuticals Hengrui Pharmaceutical